Invivyd starts Phase 2 FLINTLOCK trial of VYD2311 for long COVID, post-vaccination syndrome

Bitget2026/10/14 11:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Invivyd launched FLINTLOCK, a Phase 2 trial of VYD2311 for Long COVID or post-vaccination syndrome.
Safety and potential clinical benefit will be assessed versus placebo over 90 days in adults aged 18-65.
Initial readout is expected in mid-2027; no results have been presented yet.
Program expands VYD2311’s development beyond prevention, targeting a large unmet-need population with limited treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140701PRIMZONEFULLFEED9845254) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

华尔街见闻•2026/11/08 12:41